Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database
Acta Epileptol. 2025 May 23;7(1):31. doi: 10.1186/s42494-025-00223-5.
ABSTRACT
BACKGROUND: Epilepsy is a chronic neurological disorder marked by a persistent tendency to generate seizures, leading to substantial cognitive, behavioral, and psychosocial consequences. This study investigated psychiatric disorder-related adverse events (AEs) associated with antiseizure medications (ASMs) in children using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.
METHODS: This study conducted a comprehensive analysis of FAERS data from 2004 to 2024, focusing on psychiatric AEs in children with epilepsy or seizures treated with ASMs. Signal values were computed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).
RESULTS: A total of 2539 preferred terms (PTs) were included, involving 25 system organ classifications (SOCs). Nervous system, skin and subcutaneous tissue, and psychiatric disorders are the three most common SOCs for ASMs in children. There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships. Psychotic symptoms (notably lorazepam and topiramate, n = 116 and 109), substance dependence and abuse (notably pregabalin and clonazepam, n = 291 and 110), and the other neuropsychiatric symptoms (notably levetiracetam and valproic acid, n = 70 and 62) were the common types of psychiatric disorder-related AEs of ASMs in children. A total of nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children.
CONCLUSIONS: This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use.
Nat Commun. 2025 May 22;16(1):4766. doi: 10.1038/s41467-025-59877-x.ABSTRACTThe IPCC's Sixth Assessment Report highlights the reliance on sustainable socio-economic pathways to meet the 1.5 °C or 2...
Alcohol Clin Exp Res (Hoboken). 2025 May 22. doi: 10.1111/acer.70076. Online ahead of print.ABSTRACTBACKGROUND: Rodent models have explored the transition from controlled goal-directed consumption to...
Int J Equity Health. 2025 May 22;24(1):146. doi: 10.1186/s12939-025-02485-4.ABSTRACTThe objective of this study is to analyze the changes in catastrophic health expenditures (CHE) and out-of-pocket...
Subst Abuse Treat Prev Policy. 2025 May 22;20(1):22. doi: 10.1186/s13011-025-00652-y.ABSTRACTBACKGROUND: The aim of the study was to assess the prevalence, drug education, and associated individual...
BMC Pediatr. 2025 May 22;25(1):410. doi: 10.1186/s12887-025-05677-7.ABSTRACTBACKGROUND: Firearm-related injuries represent a growing public health crisis disproportionately affecting Black youth in the United States. While research...
Intern Emerg Med. 2025 May 22. doi: 10.1007/s11739-025-03980-w. Online ahead of print.ABSTRACTOBJECTIVES: This study investigated the patient safety of prehospital Emergency Medical Service (EMS) non-conveyance...
